BREAST Cancer Network Australia (BCNA) supports the recommendation for government subsidy of the breast cancer drug Enhertu, yet urges AstraZeneca to lower costs. The drug is inaccessible to many due to high co-payments. BCNA calls for swift PBS listing. Enhertu targets HER2-low metastatic breast cancer, offering crucial treatment options. Patients face financial burden and delays. System reform is needed for faster access.
Men’s violence action urged
